Bedel Financial Consulting’s Teva Pharmaceuticals TEVA Stock Holding History

Bedel Financial Consulting’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-925	Closed	-$9K	–	819
2022 Q1	$9K	Hold	925	–	–	﹤0.01%	699
2021 Q4	$7K	Hold	925	–	–	﹤0.01%	737
2021 Q3	$9K	Hold	925	–	–	﹤0.01%	696
2021 Q2	$9K	Buy	925 +650	+236%	+$6.88K	﹤0.01%	697
2021 Q1	$3K	Hold	275	–	–	﹤0.01%	817
2020 Q4	$3K	Hold	275	–	–	﹤0.01%	722
2020 Q3	$2K	Hold	275	–	–	﹤0.01%	739
2020 Q2	$3K	Hold	275	–	–	﹤0.01%	663
2020 Q1	$2K	Hold	275	–	–	﹤0.01%	705
2019 Q4	$3K	Hold	275	–	–	﹤0.01%	660
2019 Q3	$2K	Hold	275	–	–	﹤0.01%	675
2019 Q2	$3K	Hold	275	–	–	﹤0.01%	626
2019 Q1	$4K	Hold	275	–	–	﹤0.01%	600
2018 Q4	$4K	Hold	275	–	–	﹤0.01%	571
2018 Q3	$6K	Hold	275	–	–	﹤0.01%	537
2018 Q2	$7K	Hold	275	–	–	0.01%	518
2018 Q1	$5K	Buy	+275	New	+$5.37K	﹤0.01%	547

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Bedel Financial Consulting's TEVA Position: Q2 2022 in Review

Bedel Financial Consulting sold out of Teva Pharmaceuticals (TEVA) in Q2 2022, closing a stake of 925 shares — an estimated $9K sold.

Bedel Financial Consulting first reported a position in TEVA in Q1 2018 and held it in 17 quarters. The position peaked at $9K in Q1 2022. 456 funds tracked by Wall St. Rank hold TEVA as of Q2 2022.

Bedel Financial Consulting reported no remaining Teva Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Bedel Financial Consulting sold 925 Teva Pharmaceuticals shares in Q2 2022, an estimated $9K.
Bedel Financial Consulting first reported a position in Teva Pharmaceuticals in Q1 2018 and held it in 17 quarters.
Bedel Financial Consulting's Teva Pharmaceuticals position peaked at $9K in Q1 2022.
456 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2022.

Based on Bedel Financial Consulting's 13F filing for Q2 2022, filed 4 Aug 2022.